A silicone biomedical device is disclosed. The silicone biomedical device includes a polymerization product of a biomedical device-forming mixture containing (a) one or more grafted glycosaminoglycan polymers including a glycosaminoglycan having a polymer backbone and one or more side chains comprising an ethylenically unsaturated reactive-containing residue grafted onto the polymer backbone, and (b) one or more silicone biomedical device-forming monomers comprising at least one hydrogen donating group.
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
2.
SILICONE BIOMEDICAL DEVICE WITH POLYMERIZABLE GLYCOSAMINOGLYCANS
A silicone biomedical device is disclosed. The silicone biomedical device includes a polymerization product of a biomedical device-forming mixture containing (a) one or more grafted glycosaminoglycan polymers including a glycosaminoglycan having a polymer backbone and one or more side chains comprising an ethylenically unsaturated reactive-containing residue grafted onto the polymer backbone, and (b) one or more silicone biomedical device-forming monomers comprising at least one hydrogen donating group.
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
Methods of administering a liquid formulation of an ophthalmic agent to a topical ocular location of an eye are provided. Aspects of the methods include delivering to the topical ocular location a dose of the liquid formulation that can be wholly accommodated by the tear film of the eye. Devices and kits for practicing the methods are also provided. The methods, compositions and kits find use in a variety of applications, including therapeutic, diagnostic and cosmetic applications. Further aspects include wireless communication between a handheld dispenser of the ophthalmic agent and external devices(s) to provide various functions.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
A preloaded intraocular lens system (IOL) system, including an inserter element having a IOL operatively disposed relative thereto, a non-vapor-permeable packaging in an open state having the inserter element and the IOL disposed therein, and a vapor permeable packaging having the non-vapor-permeable packaging enclosed therein. The non-vapor permeable packaging is sealed while it is disposed in the vapor permeable packaging, while the vapor permeable packaging is sealed.
A preloaded intraocular lens system (IOL) system (100), including an inserter element (110) having a IOL (120) operatively disposed relative thereto, a non-vapor-permeable packaging (130) in an open state having the inserter element (110) and the IOL (120) disposed therein, and a vapor permeable packaging (140) having the non- vapor-permeable packaging (130) enclosed therein. The non-vapor permeable packaging (130) is sealed while it is disposed in the vapor permeable packaging (140), while the vapor permeable packaging (130) is sealed.
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
10.
COMPOSITIONS AND METHODS FOR TREATING EYETEAR FILM DEFICIENCY AND REDEYE
The present disclosure relates to compositions and methods for treating dry eye conditions caused by, e.g., tear film deficiencies in the eye, in combination with inducing vascoconstriction to treat ocular conditions such as red eye (conjunctival hyperemia), by applying to the eye or the surrounding area an oil in water emulsion composition comprising brimonidine, and optionally comprising a demulcent such as a hyaluronic acid compound.
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
11.
COMPOSITIONS AND METHODS FOR TREATMENT OF OCULAR DISORDERS
Disclosed herein are ophthalmic compositions, such as non-aqueous liquid ophthalmic compositions, comprising lifitegrast, and at least one semifluorinated alkane, such as 1-perfluorohexyloctane (F6H8), as well as methods of treatment or prevention of at least one ocular disorder, such as dry eye disease, with such compositions. The ophthalmic compositions may further be provided in a container closure system, such as a polypropylene (PP) bottle, or in a kit.
Disclosed herein are ophthalmic compositions, such as non-aqueous liquid ophthalmic compositions, comprising lifitegrast, and at least one semifluorinated alkane, such as 1-perfluorohexyloctane (F6H8), as well as methods of treatment or prevention of at least one ocular disorder, such as dry eye disease, with such compositions. The ophthalmic compositions may further be provided in a container closure system, such as a polypropylene (PP) bottle, or in a kit.
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61L 12/00 - Methods or apparatus for disinfecting or sterilising contact lensesAccessories therefor
The present disclosure describes formulations and methods for hydrating dry eyes. The formulations comprise brimonidine, at least one natural humectant, at least one amino acid, and at least one vitamin, wherein the formulation is preservative free, and may provide effective redness reduction, hydration, lubrication, and/or nourishment of the eyes.
A visible light absorbing azo compound having a structure of Formula I:
A visible light absorbing azo compound having a structure of Formula I:
A visible light absorbing azo compound having a structure of Formula I:
wherein X1, X2, X3, Y and Z are as defined herein, and ophthalmic devices formed therefrom.
C07C 245/08 - Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene
C09B 29/01 - Monoazo dyes prepared by diazotising and coupling characterised by the diazo component
C09B 29/12 - Monoazo dyes prepared by diazotising and coupling from coupling components containing hydroxy as the only directing group of the benzene series
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
The present invention relates to a shelf-stable veterinary formulation for promoting eye health and/or comfort in a companion animal consisting of a palatable ductile chewable veterinary composition comprising an omega-3 fatty acid oil; at least one anti-inflammatory plant extract; and at least one carotenoid. The present invention also relates to methods of promoting eye health and/or comfort in a companion animal using such compositions.
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
An ophthalmic device which is a polymerization product of a monomeric mixture including (a) one or more heterocyclic monomers having an ethylenically unsaturated reactive end group, (b) one or more aromatic monomers having an ethylenically unsaturated reactive end group, and (c) one or more crosslinking agents, wherein the ophthalmic device has a refractive index of greater than or equal to about 1.50.
C08F 126/02 - Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
C08L 33/06 - Homopolymers or copolymers of esters of esters containing only carbon, hydrogen, and oxygen, the oxygen atom being present only as part of the carboxyl radical
An ophthalmic device which is a polymerization product of a monomeric mixture including (a) one or more heterocyclic monomers having an ethylenically unsaturated reactive end group, (b) one or more aromatic monomers having an ethylenically unsaturated reactive end group, and (c) one or more crosslinking agents, wherein the ophthalmic device has a refractive index of greater than or equal to about 1.50.
Membrane actuated hydrodynamic dispensing system devices are disclosed. Aspects of the dispensing devices include an ampoule assembly and an actuator. The ampoule assembly contains liquid to be dispensed and includes the actuated membrane, one or more flexible apertures, and a stationary member to seal the aperture. The actuator is configured to vibrate the membrane to hydrodynamic excite the fluid contained in the ampoule assembly. Once the fluid is hydrodynamically excited sufficiently, the liquid is dispensed out of the aperture.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
A packaging system for the storage of an unused ophthalmic device is disclosed. The packaging system includes a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution that includes hyaluronic acid or a salt or a derivative thereof and tremella. The aqueous packaging solution has an osmolality of at least about 150 mOsm/kg, a pH of about 6 to about 9 and is sterilized.
A packaging system for the storage of an unused ophthalmic device is disclosed. The packaging system includes a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution that includes hyaluronic acid or a salt or a derivative thereof and tremella. The aqueous packaging solution has an osmolality of at least about 150 mOsm/kg, a pH of about 6 to about 9 and is sterilized.
A61L 12/08 - Methods or apparatus for disinfecting or sterilising contact lensesAccessories therefor using chemical substances
A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
B65B 25/00 - Packaging other articles presenting special problems
C11D 3/00 - Other compounding ingredients of detergent compositions covered in group
An ophthalmic lens having a central zone and a peripheral zone. The central zone having a first region characterized by a substantially constant first optical power and a second region disposed radially outward of the first region having periodic positive and negative deviations in power as a function of radial position, relative to the substantially constant first power. The peripheral zone disposed radially outward of the central zone. The peripheral zone having periodic positive and negative deviations relative to an average optical power, the average optical power increasing as a function of radius from the first power.
An ophthalmic lens having a central zone and a peripheral zone. The central zone having a first region characterized by a substantially constant first optical power and a second region disposed radially outward of the first region having periodic positive and negative deviations in power as a function of radial position, relative to the substantially constant first power. The peripheral zone disposed radially outward of the central zone. The peripheral zone having periodic positive and negative deviations relative to an average optical power, the average optical power increasing as a function of radius from the first power.
Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07C 317/48 - SulfonesSulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
C07D 217/02 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines
C07D 217/04 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
C07D 217/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D 405/10 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
A contact lens treating solution includes (a) about 0.005 to about 2 wt. %, based on the total weight of the contact lens treating solution, of hyaluronic acid or a salt thereof; (b) about 0.01 to about 1 wt. %, based on the total weight of the contact lens treating solution, of erythritol; (c) one or more nonionic surfactants; (d) sodium chloride, potassium chloride or any combination thereof; and (e) one or more buffers.
A01N 37/52 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing groups, e.g. carboxylic acid amidines
A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
A61K 9/00 - Medicinal preparations characterised by special physical form
A packaging system for the storage of an ophthalmic device is disclosed. The packaging system includes a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution containing (a) one or more osmoprotectants, (b) one or more poloxamer comfort agents and (c) one or more polyol demulcents, wherein the aqueous packaging solution has an osmolality of at least about 150 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.
A modular handheld fluid dispensing system is disclosed. The system can include a fluid cartridge including an ampoule, a reservoir in fluid communication with the ampoule, an aperture designed to be selectively opened to allow fluid from the ampoule and accommodated in the reservoir to be dispensed therethrough, and an actuator designed to impart vibrations to the fluid cartridge to generate hydrodynamic pressure in the fluid to open the aperture and dispense the fluid; a control cartridge can be removably coupled to the fluid cartridge, the control cartridge including a power source and controller to initiate actuation of the actuator; and a cover pivotally moveable between a closed configuration to prevent fluid from being dispensed through the aperture and an open configuration to permit the power source to be activated.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
34.
RIGID GAS PERMEABLE PREPOLYMER AND RIGID GAS PERMEABLE CONTACT LENS FORMED THEREFROM
A rigid gas permeable prepolymer comprising a reaction product of (a) a rigid gas permeable-forming prepolymer comprising (i) monomeric units derived from a bulky siloxane monomer containing an ethylenically unsaturated reactive end group, and (ii) monomeric units derived from a hydrophilic monomer having one or more reactive functionalities and an ethylenically unsaturated reactive end group, and (b) a monomer having a reactive functionality complementary to one of the one or more reactive functionalities of the hydrophilic monomer and a polymerizable ethylenically unsaturated reactive end group complementary to an ethylenically unsaturated reactive group of a rigid gas permeable contact lens-forming comonomer. Rigid gas permeable contact lenses formed from the rigid gas permeable prepolymers are also disclosed.
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
35.
RIGID GAS PERMEABLE PREPOLYMER AND RIGID GAS PERMEABLE CONTACT LENS FORMED THEREFROM
A rigid gas permeable prepolymer comprising a reaction product of (a) a rigid gas permeable-forming prepolymer comprising (i) monomeric units derived from a bulky siloxane monomer containing an ethylenically unsaturated reactive end group, and (ii) monomeric units derived from a hydrophilic monomer having one or more reactive functionalities and an ethylenically unsaturated reactive end group, and (b) a monomer having a reactive functionality complementary to one of the one or more reactive functionalities of the hydrophilic monomer and a polymerizable ethylenically unsaturated reactive end group complementary to an ethylenically unsaturated reactive group of a rigid gas permeable contact lens-forming comonomer. Rigid gas permeable contact lenses formed from the rigid gas permeable prepolymers are also disclosed.
C08F 230/08 - Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal containing silicon
B29D 11/00 - Producing optical elements, e.g. lenses or prisms
B29K 33/00 - Use of polymers of unsaturated acids or derivatives thereof, as moulding material
B29K 105/00 - Condition, form or state of moulded material
The present invention provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 9/00 - Medicinal preparations characterised by special physical form
42 - Scientific, technological and industrial services, research and design
Goods & Services
Provision of access to e-commerce platforms on the Internet in the eye and vision care fields Platform as a service (PAAS) featuring computer software platforms for providing, using, and accessing an eCommerce platform in the eye and vision care fields; Providing a web site featuring technology that enables users to purchase goods in the eye and vision care fields
A monofunctional silicone monomer is represented by a structure of Formula I:
A monofunctional silicone monomer is represented by a structure of Formula I:
A monofunctional silicone monomer is represented by a structure of Formula I:
wherein R1, R2, R3, R4, R5, R6, R7, x and y are as defined herein. An ophthalmic device having optical clarity is a polymerization product of a monomeric mixture includes (a) one or more of the monofunctional silicone monomers represented by a structure of Formula I, and (b) one or more ophthalmic device-forming hydrophilic comonomers.
C08F 230/08 - Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal containing silicon
A silicone hydrogel which is a polymerization product of a monomeric mixture including (a) one or more monofunctional silicone monomers represented by a structure of Formula I:
A silicone hydrogel which is a polymerization product of a monomeric mixture including (a) one or more monofunctional silicone monomers represented by a structure of Formula I:
A silicone hydrogel which is a polymerization product of a monomeric mixture including (a) one or more monofunctional silicone monomers represented by a structure of Formula I:
wherein R1, R2, R3 and R4 are independently hydrogen, a C1 to C12 alkyl group, a C1 to C12 halo alkyl group, a C3 to C12 cycloalkyl group, a C3 to C12 heterocycloalkyl group, a C2 to C12 alkenyl group, a C2 to C12 haloalkenyl group, a C6 to C12 aryl group and a C6 to C12 heteroaryl group; R5, R6 and R7 are independently a straight or branched C1 to C12 alkyl group, x is from 1 to 6, and y is from 3 to 15, and (b) one or more silicone hydrogel-forming silicone comonomers.
C08G 77/26 - Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen, and oxygen nitrogen-containing groups
C08G 77/50 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon in which at least two but not all the silicon atoms are connected by linkages other than oxygen atoms by carbon linkages
[00219] A silicone hydrogel is a polymerization product of a monomeric mixture including (a) one or more monofunctional silicone monomers represented by a structure of Formula I: (I) wherein R1, R2, R3and R41121123 123122122 126126 1212 heteroaryl group; R5, R6and R711212 alkyl group, x is from 1 to 6, and y is from 3 to 15, and (b) one or more silicone hydrogel-forming silicone comonomers.
C08G 77/26 - Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen, and oxygen nitrogen-containing groups
C08L 83/08 - Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen, and oxygen
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
46.
MONOFUNCTIONAL SILICONE MONOMERS AND SILICONE HYDROGELS FORMED THEREFROM
A monofunctional silicone monomer is represented by a structure of Formula I: (I) wherein R1, R2, R3, R4, R5, R6, R7, x and y are as defined herein. An ophthalmic device having optical clarity is a polymerization product of a monomeric mixture includes (a) one or more of the monofunctional silicone monomers represented by a structure of Formula I, and (b) one or more ophthalmic device-forming hydrophilic comonomers.
C08G 77/26 - Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen, and oxygen nitrogen-containing groups
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
47.
1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF
Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutical composition described herein.
Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutical composition described herein.
C07D 217/02 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A method for preparing a contact lens containing an ultraviolet (UV) blocker is disclosed. The method involves (a) polymerizing a monomeric mixture comprising (i) one or more contact lens-forming comonomers, and (ii) one or more UV blockers comprising a phenolic group having a protected hydroxyl moiety and one or more ethylenically unsaturated reactive groups to obtain a polymerization product comprising the one or more UV blockers comprising a phenolic group having a protected hydroxyl moiety, and (b) deprotecting the protected hydroxyl moiety of the one or more UV blockers of the polymerization product.
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
B29D 11/00 - Producing optical elements, e.g. lenses or prisms
A method for preparing a contact lens containing an ultraviolet (UV) blocker is disclosed. The method involves (a) polymerizing a monomeric mixture comprising (i) one or more contact lens-forming comonomers, and (ii) one or more UV blockers comprising a phenolic group having a protected hydroxyl moiety and one or more ethylenically unsaturated reactive groups to obtain a polymerization product comprising the one or more UV blockers comprising a phenolic group having a protected hydroxyl moiety, and (b) deprotecting the protected hydroxyl moiety of the one or more UV blockers of the polymerization product.
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
51.
Hydrodynamically Actuated Preservative Free Dispensing System Having a Collapsible Liquid Reservoir
Multi-dose preservative-free ocular fluid delivery devices are provided. The fluid delivery device includes a fluid dispensing system and a fluid package for storing a liquid therein and supplying said liquid to the dispensing system. The dispensing system comprises an elongated chamber which includes a check valve which defines a frontal closure to the chamber. The valve is normally closed and hermetically seals the chamber. The dispenser includes a vibration motor that induces oscillations to the chamber and to the fluid within. The oscillations of the chamber impart momentum to the fluid stored in the chamber which in turn imparts force that cyclically opens the valve to dispense streams or liquid droplets. Fluid is dispensed only when the motor oscillates while otherwise the valve is hermetically closed. The fluid package can be made collapsible to remove the need to vent it.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes DetailsAccessories therefor
52.
OPHTHALMIC DEVICES HAVING A HIGH REFRACTIVE INDEX AND ABBE NUMBER
An ophthalmic device which is a polymerization product of a monomeric mixture includes (a) from about 30 to about 75 weight percent, based on the total weight of the monomeric mixture, of one or more cycloaliphatic (meth)acrylic monomers; (b) greater than about 25 weight percent, based on the total weight of the monomeric mixture, of one or more hydrophilic monomers; and (c) one or more crosslinking agents, wherein the ophthalmic device has a refractive index of about 1.48 to about 1.52 and an Abbe number greater than or equal to 50.
A packaging system for the storage of an ophthalmic device is disclosed. The packaging system includes a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution that includes ectoine or an ophthalmologically acceptable ectoine derivative. The aqueous packaging solution has an osmolality of at least about 150 mOsm/kg, a pH of about 6 to about 9 and is sterilized.
An ophthalmic device which is a polymerization product of a monomeric mixture includes (a) from about 30 to about 75 weight percent, based on the total weight of the monomeric mixture, of one or more cycloaliphatic (meth)acrylic monomers; (b) greater than about 25 weight percent, based on the total weight of the monomeric mixture, of one or more hydrophilic monomers; and (c) one or more crosslinking agents, wherein the ophthalmic device has a refractive index of about 1.48 to about 1.52 and an Abbe number greater than or equal to 50.
The present disclosure describes compositions comprising vitamin C, vitamin E, zinc, copper, lutein, zeaxanthin, and coenzyme Q10, and pharmaceutically acceptable salts of any of the foregoing. The compositions are useful in methods for treating conditions associated with a loss of visual acuity including, for example, age-related macular degeneration as well as supporting heart health.
Multi-dose preservative-free ocular fluid delivery devices are provided. The fluid delivery device includes a fluid dispensing system and a fluid package for storing a liquid therein and supplying said liquid to the dispensing system. The dispensing system comprises an elongated chamber which includes a check valve which defines a frontal closure to the chamber. The valve is normally closed and hermetically seals the chamber. The dispenser includes a vibration motor that induces oscillations to the chamber and to the fluid within. The oscillations of the chamber impart momentum to the fluid stored in the chamber which in turn imparts force that cyclically opens the valve to dispense streams or liquid droplets. Fluid is dispensed only when the motor oscillates while otherwise the valve is hermetically closed.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
B05B 1/30 - Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to control volume of flow, e.g. with adjustable passages
A biomedical device having a surface coating includes a bulk material having one or more biomedical device surface reactive functional groups and/or one or more biomedical device surface protected reactive functional groups and a surface coating. The surface coating is derived from a block copolymer including (a) monomeric units derived from an ethylenically unsaturated containing monomer having ring-opening reactive functionalities or nucleofugic functionalities that are complementary to the one or more biomedical device surface reactive functional groups and the one or more biomedical device surface protected reactive functional groups, and (b) monomeric units derived from an ethylenically unsaturated-containing hydrophilic monomer.
C09D 153/00 - Coating compositions based on block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bondsCoating compositions based on derivatives of such polymers
C08F 293/00 - Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
A biomedical device having a surface coating includes a bulk material having one or more biomedical device surface reactive functional groups and/or one or more biomedical device surface protected reactive functional groups and a surface coating. The surface coating is derived from a block copolymer including (a) monomeric units derived from an ethylenically unsaturated containing monomer having ring-opening reactive functionalities or nucleofugic functionalities that are complementary to the one or more biomedical device surface reactive functional groups and the one or more biomedical device surface protected reactive functional groups, and (b) monomeric units derived from an ethylenically unsaturated-containing hydrophilic monomer.
B29D 11/00 - Producing optical elements, e.g. lenses or prisms
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
The present disclosure describes compositions comprising vitamin C, vitamin E, zinc, copper, lutein, zeaxanthin, and coenzyme Q10, and pharmaceutically acceptable salts of any of the foregoing. The compositions are useful in methods for treating conditions associated with a loss of visual acuity including, for example, age-related macular degeneration as well as supporting heart health.
A contact lens treating solution includes (a) one or more potassium salts selected from the group consisting of potassium chloride, potassium citrate, potassium hydroxide, potassium borate, potassium ethylenediaminetetraacetic acid and potassium phosphate, (b) an antimicrobial agent comprising alexidine or a salt or a free base thereof, and (c) optionally, one or more sodium salts selected from the group consisting of sodium chloride, sodium citrate, sodium hydroxide, sodium phosphate, sodium ethylenediaminetetraacetic acid and sodium borate, wherein the one or more potassium salts are present in an amount greater than an amount of the one or more sodium salts when present.
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Lens design software; Contact lenses; Customized scleral contact lenses to treat eye problems, namely myopia, keratoconus, astigmatism. Orthokeratology apparatus and instruments; Keratoscopes; Orthokeratology lenses; Customized scleral contacts lenses for medical purposes to treat eye problems, namely myopia, keratoconus, astigmatism. Software platform for fitting lenses; Software as a service [SaaS] featuring software platforms for lens design; Software solutions associated with using ophthalmic instruments and for ordering and fitting lenses. Providing medical information and services in the field of orthokeratology; Fitting of contact lenses..
74.
METHODS AND APPARATUS FOR SELECTIVELY CONTROLLING MOVEMENT OF A CONTACT LENS DURING A PACKAGING PROCESS
A method of selectively controlling movement of a contact lens in blister packaging comprising a cavity, the method comprising depositing an electric charge at a location in the cavity, securing the contact lens to the blister packaging at the location with the electric charge, and after the step of securing the contact lens, injecting a lens hydrating liquid into the cavity whereby the lens is hydrated and the securing terminated. A method of selectively controlling movement of a contact lens in blister packaging comprising a cavity, the method comprising depositing a droplet of a first lens hydrating liquid in the cavity, securing the contact lens to the blister packaging with the droplet, and after the step of securing the contact lens, injecting a second lens hydrating liquid into the cavity whereby the lens is hydrated.
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Lens design software; Contact lenses; Customized scleral contact lenses to treat eye problems, namely myopia, keratoconus, astigmatism. Orthokeratology apparatus and instruments; Keratoscopes; Orthokeratology lenses; Customized scleral contacts lenses for medical purposes to treat eye problems, namely myopia, keratoconus, astigmatism. Software platform for fitting lenses; Software as a service [SaaS] featuring software platforms for lens design; Software solutions associated with using ophthalmic instruments and for ordering and fitting lenses. Providing medical information and services in the field of orthokeratology; Fitting of contact lenses..
76.
Methods for selectively controlling movement of a contact lens during a packaging process
A method of selectively controlling movement of a contact lens in blister packaging comprising a cavity, the method comprising depositing an electric charge at a location in the cavity, securing the contact lens to the blister packaging at the location with the electric charge, and after the step of securing the contact lens, injecting a lens hydrating liquid into the cavity whereby the lens is hydrated and the securing terminated. A method of selectively controlling movement of a contact lens in blister packaging comprising a cavity, the method comprising depositing a droplet of a first lens hydrating liquid in the cavity, securing the contact lens to the blister packaging with the droplet, and after the step of securing the contact lens, injecting a second lens hydrating liquid into the cavity whereby the lens is hydrated.
B65B 25/00 - Packaging other articles presenting special problems
B29D 11/00 - Producing optical elements, e.g. lenses or prisms
B65B 9/04 - Enclosing successive articles, or quantities of material, between opposed webs one or both webs being formed with pockets for the reception of the articles, or of the quantities of material
B65B 35/56 - Orientating, i.e. changing the attitude of, articles, e.g. of non-uniform cross-section
B65B 55/22 - Immersing contents in protective liquids
B65B 61/00 - Auxiliary devices, not otherwise provided for, for operating on sheets, blanks, webs, binding material, containers or packages
B65D 81/22 - Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient in moist conditions or immersed in liquids
B65D 85/00 - Containers, packaging elements or packages, specially adapted for particular articles or materials
A contact lens treating solution includes (a) one or more potassium salts selected from the group consisting of potassium chloride, potassium citrate, potassium hydroxide, potassium borate, potassium ethylenediaminetetraacetic acid and potassium phosphate, (b) an antimicrobial agent comprising alexidine or a salt or a free base thereof, and (c) optionally, one or more sodium salts selected from the group consisting of sodium chloride, sodium citrate, sodium hydroxide, sodium phosphate, sodium ethylenediaminetetraacetic acid and sodium borate, wherein the one or more potassium salts are present in an amount greater than an amount of the one or more sodium salts when present.
A contact lens package, comprising blister packaging defining a cavity, a contact lens disposed in an unstressed state within the cavity, lens hydrating liquid partially filling the cavity, and lid stock sealed to the blister packaging such that a segment of the lid stock, in combination with the cavity, forms an enclosure of the lens and the liquid. The segment has an interior surface including at least one relief element. The interior surface exclusive of the at least one relief element is flat. An air gap is disposed between a top surface of the liquid and at least a portion of the interior surface. The at least one relief element on the interior surface of the lid stock may be formed while testing the structure for leaks by applying pressure to the lid stock with a stamp having a contour corresponding to the at least one relief element.
B65D 75/00 - Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
A45C 11/00 - Receptacles for purposes not provided for in groups
79.
Hydrodynamically actuated preservative free dispensing system
Multi-dose preservative-free ocular fluid delivery devices are provided. The fluid delivery device includes a fluid dispensing system and a fluid package for storing a liquid therein and supplying said liquid to the dispensing system. The dispensing system comprises an elongated chamber which includes a check valve which defines a frontal closure to the chamber. The valve is normally closed and hermetically seals the chamber. The dispenser includes a vibration motor that induces oscillations to the chamber and to the fluid within. The oscillations of the chamber impart momentum to the fluid stored in the chamber which in turn imparts force that cyclically opens the valve to dispense streams or liquid droplets. Fluid is dispensed only when the motor oscillates while otherwise the valve is hermetically closed.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61B 17/00 - Surgical instruments, devices or methods
An ophthalmically compatible solution includes (a) about 0.005 to about 2 wt. %, based on the total weight of the ophthalmically compatible solution, of hyaluronic acid or a salt thereof; (b) about 0.01 to about 1 wt. %, based on the total weight of the ophthalmically compatible solution, of erythritol; (c) sodium chloride, potassium chloride or any combination thereof; and (d) one or more buffers.
A01N 37/52 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing groups, e.g. carboxylic acid amidines
A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention relates to compositions and methods for treating tear film deficiencies in the eye by applying to the eye or the surrounding area an oil in water emulsion composition, optionally comprising a demulcent such as a hyaluronic acid compound.
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present invention relates to compositions and methods for treating tear film deficiencies in the eye by applying to the eye or the surrounding area a composition comprising hyaluronic acid.
The present invention relates to methods for treating tear film deficiencies in the eye by applying to the eye or the surrounding area an oil in water emulsion composition, optionally comprising a demulcent such as a hyaluronic acid compound.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present invention relates to methods for treating tear film deficiencies in the eye by applying to the eye or the surrounding area a composition comprising hyaluronic acid.
A contact lens treating solution includes (a) one or more of tris(hydroxymethyl)aminomethane, bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane and a salt thereof; and (b) one or more antimicrobial agents comprising one or more polyquaternium polymers.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Online retail store services featuring eye and vision care products, namely, contact lenses, contact lens solutions, eye drops, and cosmetic preparations for the care of the eye area, available through an ecommerce platform Provision of access to e-commerce platforms on the Internet in the eye and vision care fields Platform as a service (PAAS) featuring computer software platforms for providing, using, and accessing an eCommerce platform in the eye and vision care fields; Providing a web site featuring technology that enables users to purchase goods in the eye and vision care fields
42 - Scientific, technological and industrial services, research and design
Goods & Services
Online retail store services in the field of eye and vision care available through an ecommerce platform Provision of access to e-commerce platforms on the Internet in the eye and vision care fields Platform as a service (PAAS) featuring computer software platforms for providing, using, and/or accessing an eCommerce platform in the eye and vision care fields; Providing a web site featuring technology that enables users to purchase goods in the eye and vision care fields
The present disclosure describes formulations and methods for hydrating dry eyes. The formulations comprise at least one natural humectant, at least one amino acid, and at least one vitamin, wherein the formulation is preservative free, and may provide effective hydration, lubrication, and/or nourishment of the eyes.
An injector for injecting an IOL into an eye, comprising an injector body having a lumen wall defining a lumen, a plunger (140) having a longitudinal axis and a soft tip (142) at a distal end of the plunger. The soft tip having a concave distal surface (C). In a plane including the longitudinal axis (LA), the plane being perpendicular to an IOL optical axis when the IOL is located at a staging area of the injector body, the concave distal surface extending in a direction at a non¬ perpendicular angle relative to the longitudinal axis. The concave distal surface may be oval-shaped in a plane perpendicular to the direction, and the concave distal surface has no curvature along the direction.
Micro-droplet delivery devices and methods are described where the device may comprise a piezoelectric actuator having a piezoelectric chip that is operatively coupled to a drug package under a preloading force. The actuator is configured to generate an acoustic pressure within the drug package to dispense droplets of an agent from an aperture, e.g., to the corneal surface of the eye. The piezoelectric actuator can be coupled or decoupled from the drug package.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
The present disclosure describes formulations and methods for hydrating dry eyes. The formulations comprise at least one natural humectant, at least one amino acid, and at least one vitamin, wherein the formulation is preservative free, and may provide effective hydration, lubrication, and/or nourishment of the eyes.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
An injector for injecting an IOL into an eye, comprising an injector body having a lumen wall defining a lumen, a plunger having a longitudinal axis and a soft tip at a distal end of the plunger. The soft tip having a concave distal surface. In a plane including the longitudinal axis, the plane being perpendicular to an IOL optical axis when the IOL is located at a staging area of the injector body, the concave distal surface extending in a direction at a non-perpendicular angle relative to the longitudinal axis. The concave distal surface may be oval-shaped in a plane perpendicular to the direction, and the concave distal surface has no curvature along the direction.
An ophthalmic surgical handpiece includes a needle for insertion through an incision in an eye and a generator of ultrasonic energy for supplying the ultrasonic energy to the needle to emulsify tissue within the eye. The ophthalmic surgical handpiece also includes a sleeve surrounding at least a portion of the needle, the sleeve including an insertion portion for supplying infusion fluid into the eye and a compressible portion for sealing the incision in the eye by pushing against an exterior surface of the eye at the incision.
Occlusion detection in a vacuum-based system for ophthalmic surgery includes a handpiece and aspiration and irrigation subsystems. The aspiration subsystem includes an aspiration line coupled to a handpiece, an aspiration pressure transducer, and a vacuum-based aspiration pump. The irrigation subsystem includes an irrigation line coupled to an irrigation source having an irrigation fluid, a handpiece, an irrigation pressure transducer, and a positive displacement pump. The system also includes a processor coupled to the positive displacement pump and a memory coupled to the processor. The memory includes executable instructions that cause the processor to determine a flow rate of irrigation fluid through the irrigation line, based on a rotation rate of the positive displacement pump, and provide an occlusion warning when the flow rate is below a threshold level and a vacuum is being commanded.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A contact lens treating solution includes (a) one or more of tris(hydroxymethyl)aminomethane, bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane and a salt thereof; and (b) one or more antimicrobial agents comprising one or more polyquaternium polymers.
An ophthalmic lens, comprising a central zone having at least a first power, and a peripheral zone having an add-power offset relative to the at least first power and a spatially-modulated optical parameter. In some embodiments, the central zone has a diameter in the range 2.0 to 5.0 mm. In some embodiments, the central zone is not more than 1 mm smaller than a wearer's pupil. The spatially-modulated optical parameter may include optical power, light scattering or light transmission.
Occlusion detection in a vacuum-based system for ophthalmic surgery includes a handpiece and aspiration and irrigation subsystems. The aspiration subsystem includes an aspiration line coupled to a handpiece, an aspiration pressure transducer, and a vacuum-based aspiration pump. The irrigation subsystem includes an irrigation line coupled to an irrigation source having an irrigation fluid, a handpiece, an irrigation pressure transducer, and a positive displacement pump. The system also includes a processor coupled to the positive displacement pump and a memory coupled to the processor. The memory includes executable instructions that cause the processor to determine a flow rate of irrigation fluid through the irrigation line, based on a rotation rate of the positive displacement pump, and provide an occlusion warning when the flow rate is below a threshold level and a vacuum is being commanded.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
